<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="446">
  <stage>Registered</stage>
  <submitdate>7/09/2005</submitdate>
  <approvaldate>9/09/2005</approvaldate>
  <actrnumber>ACTRN12605000343606</actrnumber>
  <trial_identification>
    <studytitle>Nitric Oxide Laboratory Animal Allergy Study</studytitle>
    <scientifictitle>Use of serial exhaled nitric oxide measurements in detecting airways inflammation in subjects exposed to laboratory animals during a typical working week</scientifictitle>
    <utrn />
    <trialacronym>NOLAA</trialacronym>
  </trial_identification>
  <conditions>
    <healthcondition>Laboratory Animal Allergy</healthcondition>
    <healthcondition>Asthma</healthcondition>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Allergies</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Asthma</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>None</interventions>
    <comparator />
    <control />
    <interventioncode>None</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To assess whether exhaled nitric oxide levels are elevated in laboratory workers with laboratory animal allergy</outcome>
      <timepoint />
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To assess whether exhaled nitric oxide levels in exposed laboratory workers increase during the working week and whether this increase is a sensitive marker of early airways disease in laboratory animal allergy.</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria> Subjects working with laboratory animals &gt;2 days per week and for a duration of at least 6 months.</inclusivecriteria>
    <inclusiveminage>0</inclusiveminage>
    <inclusiveminagetype>Not stated</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Oral or inhaled steroids within the last 6 weeks.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs>Natural history</purposeobs>
    <duration>Cross-sectional</duration>
    <selection>Defined population</selection>
    <timing>Both</timing>
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>6/02/2005</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>50</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>ACC New Zealand</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>New Zealand</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Accident and Compensation Corporation New Zealand</fundingname>
      <fundingaddress />
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>University</sponsortype>
      <sponsorname>University of Otago</sponsorname>
      <sponsoraddress />
      <sponsorcountry>New Zealand</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Professor D Robin Taylor</name>
      <address>Otago Respiratory Research Group
Dunedin School of Medicine
University of Otago
PO Box 913
Dunedin</address>
      <phone>+64 3 4740999 (Ext. 8785)</phone>
      <fax />
      <email>robin.taylor@stonebow.otago.ac.nz</email>
      <country>New Zealand</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Richard Hewitt</name>
      <address>Otago Respiratory Research Group
Dunedin School of Medicine
University of Otago
PO Box 913
Dunedin</address>
      <phone>+64 3 4740999 (Ext. 8785)</phone>
      <fax />
      <email>richard.hewitt@stonebow.otago.ac.nz</email>
      <country>New Zealand</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>